Drugs Made In America Acquisition II Corp. 1Q 2026: Net income $4.34M, EPS $0.07— 10-Q Summary

About this update from Drugs Made In America Acquisition Ii Corp.

Drugs Made In America Acquisition II Corp. reported net income of $4.34M for the first quarter of 2026, a turnaround from a loss of ($59K) in the year-ago quarter; diluted earnings per share were $0.07 versus ($0) in Q1 2025. The company has not commenced operations and reported no operating revenue for the period.Financial HighlightsNet income was $4.34M for Q1 2026, versus ($59K) in Q1 2025 (turnaround to profit).Diluted EPS was $0.07 for Q1 2026 (diluted), versus ($0.00) for Q1 2025.Revenue: Not reported for Q1 2026 (Company has not commenced operations; interest income is non-operating).Business HighlightsBusiness focus: blank-check company targeting pharmaceutical industry acquisitions and seeking a strategic combination.Capital formation: completed IPO and private placement and placed approximately $500M net proceeds in a trust to fund an initial business combination.Operational activity: no operating revenues; post-IPO activities limited to target identification, due diligence and transaction preparation.Governance timeline: a 24-month Combination Period to complete a business combination; failure to do so would trigger liquidation and shareholder redemptions.Original SEC Filing: This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

View stock analysis, news, and events for Drugs Made In America Acquisition Ii Corp.